Mylan: Reduced Confidence in Ability to Achieve Prior Expectations, $20 FVE
More than 40 states have filed a price-fixing lawsuit in federal court against several generic drug manufacturers, including Teva and Mylan, but we don't expect any major changes to our fair value estimates based on the legal action because the potential range of outcomes is fairly large and difficult to predict. We continue to rate Mylan and Teva with uncertainty ratings of very high and extreme, respectively, partly related to the high debt levels these firms carry. The increased legal concern...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.